The Swedish biopharmaceutical company BioArctic Neuroscience AB is developing a novel treatment for complete spinal cord injury. This project has received funding (6.4 M€) from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 643853 to perform a clinical study in patients with a complete spinal cord injury.
Today, 2.5 million people suffer from spinal cord injuries that essentially lack effective treatment. As a result of pioneering Swedish research, a product has been developed with the potential to provide a successful neurosurgical treatment, which will hopefully improve the function and quality of life of patients suffering from spinal cord injuries.
The forthcoming product is a biodegradable device combined with a growth factor designed to support the growth of nerves in the spinal cord, as well as restoring its function. The product has been developed together with Karolinska Institutet, Elos Medtech, Ångström laboratories (Uppsala University) and Protein Sciences (US). The project has been supported by previous grants from the Swedish Government Agency for Innovation, Vinnova.
The clinical study in patients with a complete injury in the thoracic part of the spinal cord is planned to start 2015. The surgery will be performed at the Neurosurgery Clinic at Karolinska University Hospital, Sweden. The clinical study will be performed with our Nordic partners: Rehabilitation clinics in Glostrup/Hvidovre, Viborg, Denmark, Laittila, Finland and Rehabilitation Station Stockholm, Sweden.
“We are grateful for the support from Horizon 2020 and are preparing for initiation of the clinical programme of this innovative product, intended to improve the quality of life for spinal cord injury patients”, says Dr. Gunilla Osswald, CEO of BioArctic Neuroscience AB.
For further information, please see below or contact
BioArctic Neuroscience AB
Telephone: +46 8 695 69 31
Facts for the editorial staff
About BioArctic Neuroscience
BioArctic Neuroscience AB is a biopharmaceutical company carrying out research and development for new treatments of disorders in the nervous system. The company, which was founded in 2003, has a proprietary technology for therapeutic monoclonal antibodies, for the treatment of Alzheimer’s disease, Parkinson’s disease and other related neurological disorders. The most advanced project, BAN2401, is currently in late clinical development in early Alzheimer’s disease together with Eisai Co. Ltd. The company in-licensed 2008 a novel innovative treatment for spinal cord injuries, which now is progressing into clinical development. The company’s business model is to form strategic research alliances, joint ventures or license agreements with pharmaceutical industries and bring its drug candidates to the world market. The company, which is headquartered in Stockholm, has received early venture capital from Karolinska Development AB and Uppsala Holding AB.
About Spinal Cord Injury
Repair and regeneration of the chronically injured spinal cord remains a huge challenge. After traumatic spinal cord injury (SCI) the surrounding areas below the site of injury are affected by loss of neurological function and leads to a poor prognosis for functional recovery. The annual incidence of SCI is estimated to 22 per million of population. There are 2.5 million survivors of SCI and they suffer from serious handicaps that impair their quality of life, e.g., loss of motor function, sensory loss, chronic pain, infections and pressure sores.